AR128459A2 - Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación - Google Patents

Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación

Info

Publication number
AR128459A2
AR128459A2 ARP230100279A ARP230100279A AR128459A2 AR 128459 A2 AR128459 A2 AR 128459A2 AR P230100279 A ARP230100279 A AR P230100279A AR P230100279 A ARP230100279 A AR P230100279A AR 128459 A2 AR128459 A2 AR 128459A2
Authority
AR
Argentina
Prior art keywords
solid pharmaceutical
roller
manufacture
pharmaceutical composition
compressed solid
Prior art date
Application number
ARP230100279A
Other languages
English (en)
Inventor
Charu Kochhar
Jacques Quinton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR128459A2 publication Critical patent/AR128459A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12136—Balloons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/1204—Type of occlusion temporary occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A61B17/12109—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder in a blood vessel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M25/1002—Balloon catheters characterised by balloon shape
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12068—Details concerning the detachment of the occluding device from the introduction device detachable by heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/12—Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B2017/1205—Introduction devices
    • A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
    • A61B2017/12086—Details concerning the detachment of the occluding device from the introduction device magnetically detachable

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Surgical Instruments (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas sólidas que comprenden el compuesto inhibidor de fosfatidilinositol 3-quinasa, 4-(trifluorometil)-5-(2,6-dimorfolinopirimidin-4-il)piridin-2-amina o una sal aceptable para uso farmacéutico del mismo, estearil fumarato de sodio, y opcionalmente al menos un vehículo aceptable para uso farmacéutico adicional. La presente invención también se refiere a los procesos para su preparación y su uso como medicamentos para el tratamiento de cáncer.
ARP230100279A 2013-03-06 2023-02-06 Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación AR128459A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361773492P 2013-03-06 2013-03-06

Publications (1)

Publication Number Publication Date
AR128459A2 true AR128459A2 (es) 2024-05-08

Family

ID=50342366

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140100730A AR095032A1 (es) 2013-03-06 2014-03-06 Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo
ARP230100279A AR128459A2 (es) 2013-03-06 2023-02-06 Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140100730A AR095032A1 (es) 2013-03-06 2014-03-06 Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo

Country Status (28)

Country Link
US (2) US9474534B2 (es)
EP (1) EP2964200B1 (es)
JP (1) JP6313343B2 (es)
KR (1) KR102233757B1 (es)
CN (1) CN105073099B (es)
AR (2) AR095032A1 (es)
AU (1) AU2014224238B2 (es)
BR (1) BR112015021097B1 (es)
CA (1) CA2904032C (es)
CL (1) CL2015002466A1 (es)
EA (1) EA028301B1 (es)
ES (1) ES2634020T3 (es)
IL (1) IL240579B (es)
JO (1) JO3256B1 (es)
MA (1) MA38358B1 (es)
MX (1) MX370175B (es)
MY (1) MY174648A (es)
NZ (1) NZ711015A (es)
PE (1) PE20151607A1 (es)
PH (1) PH12015501945A1 (es)
PL (1) PL2964200T3 (es)
PT (1) PT2964200T (es)
SG (1) SG11201506392VA (es)
TN (1) TN2015000386A1 (es)
TW (1) TW201442712A (es)
UA (1) UA114948C2 (es)
WO (1) WO2014136048A1 (es)
ZA (1) ZA201505830B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498604B2 (en) 1997-11-12 2016-11-22 Genesis Technologies Llc Medical device and method
US10335577B2 (en) 2010-05-19 2019-07-02 Nfinium Vascular Technologies, Llc Augmented delivery catheter and method
US9561094B2 (en) 2010-07-23 2017-02-07 Nfinium Vascular Technologies, Llc Devices and methods for treating venous diseases
EP3151904A4 (en) 2014-06-04 2018-02-14 Nfinium Vascular Technologies, LLC Low radial force vascular device and method of occlusion
EP3881833B1 (en) * 2015-06-30 2023-11-01 Genentech, Inc. Immediate-release tablets containing a drug and processes for forming the tablets
FI130702B1 (en) * 2018-12-18 2024-01-26 Miikka Frant Device suitable for insertion into the vein of a human patient
US20220226300A1 (en) * 2019-05-24 2022-07-21 Eisai R&D Management Co., Ltd. A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor
WO2022066499A1 (en) * 2020-09-27 2022-03-31 Boston Scientific Scimed, Inc. Expandable guide devices, systems, and methods
WO2022170187A1 (en) 2021-02-05 2022-08-11 Pyne Devaraj Detachable balloon embolization device and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT869772E (pt) * 1995-12-27 2002-03-28 Janssen Pharmaceutica Nv Forma galenica solida bioadesiva
US5916235A (en) 1997-08-13 1999-06-29 The Regents Of The University Of California Apparatus and method for the use of detachable coils in vascular aneurysms and body cavities
EP1054635B1 (en) * 1998-02-10 2010-01-06 Artemis Medical, Inc. Occlusion, anchoring, tensioning or flow direction apparatus
US6066157A (en) 1998-09-16 2000-05-23 Medtronics Ave, Inc. Anchor joint for coaxial balloon dilatation catheter
US6368338B1 (en) 1999-03-05 2002-04-09 Board Of Regents, The University Of Texas Occlusion method and apparatus
US7331973B2 (en) 2002-09-30 2008-02-19 Avdanced Cardiovascular Systems, Inc. Guide wire with embolic filtering attachment
US7618435B2 (en) * 2003-03-04 2009-11-17 Nmt Medical, Inc. Magnetic attachment systems
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AU2009288200A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
EP2490534A4 (en) * 2009-10-23 2013-06-12 Merck Sharp & Dohme PHARMACEUTICAL COMPOSITIONS OF COMBINATIONS OF DIPEPTIDYL-PEPTIDASE-4 INHIBITORS WITH PIOGLITAZONE
US8992540B2 (en) 2010-07-22 2015-03-31 Kyphon Sarl Adjustable surgical instruments and methods of use and fabrication
WO2012060847A1 (en) * 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012166804A1 (en) 2011-06-03 2012-12-06 Reverse Medical Corporation Embolic implant and method of use
WO2014164535A1 (en) 2013-03-11 2014-10-09 Ferry Steven J A guidewire/ partial occluder for intraluminal travel

Also Published As

Publication number Publication date
TW201442712A (zh) 2014-11-16
JP6313343B2 (ja) 2018-04-18
ZA201505830B (en) 2017-07-26
MA38358A1 (fr) 2016-11-30
JO3256B1 (ar) 2018-09-16
EP2964200B1 (en) 2017-04-19
UA114948C2 (uk) 2017-08-28
US10342547B2 (en) 2019-07-09
CA2904032C (en) 2021-02-16
MY174648A (en) 2020-05-05
MA38358B1 (fr) 2017-07-31
EP2964200A1 (en) 2016-01-13
AR095032A1 (es) 2015-09-16
TN2015000386A1 (en) 2017-01-03
IL240579B (en) 2019-08-29
US20160045202A1 (en) 2016-02-18
SG11201506392VA (en) 2015-09-29
PL2964200T3 (pl) 2017-09-29
CL2015002466A1 (es) 2016-03-04
ES2634020T3 (es) 2017-09-26
MX370175B (es) 2019-12-04
PE20151607A1 (es) 2015-11-26
EA028301B1 (ru) 2017-10-31
AU2014224238B2 (en) 2016-07-14
HK1212244A1 (en) 2016-06-10
US9474534B2 (en) 2016-10-25
WO2014136048A1 (en) 2014-09-12
CN105073099B (zh) 2018-10-26
BR112015021097A2 (pt) 2017-07-18
KR102233757B1 (ko) 2021-03-30
KR20150123248A (ko) 2015-11-03
IL240579A0 (en) 2015-09-24
JP2016510065A (ja) 2016-04-04
PH12015501945B1 (en) 2016-01-11
US20160015643A1 (en) 2016-01-21
MX2015011705A (es) 2016-05-18
PH12015501945A1 (en) 2016-01-11
CA2904032A1 (en) 2014-09-12
AU2014224238A1 (en) 2015-09-03
NZ711015A (en) 2020-02-28
CN105073099A (zh) 2015-11-18
PT2964200T (pt) 2017-07-25
BR112015021097B1 (pt) 2022-08-30
EA201591649A1 (ru) 2016-01-29

Similar Documents

Publication Publication Date Title
AR128459A2 (es) Composición farmacéutica sólida comprimida por rodillo y el proceso para su fabricación
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
DOP2015000170A (es) Compuestos químicos
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
CR20160016A (es) Pirazolpiridinas sustituidas
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
CL2017002229A1 (es) Inhibidores de bace1.
TN2015000524A1 (en) Pharmaceutical compositions
GT201500189A (es) Inhibidores de autotaxina